公司新闻 - 亚科因（Abbkine）—服务于细胞和蛋白研究全球用户

首页
技术中心
产品文献

或

货号	产品名称	文献标题	IF	杂志名称
BMU102	SuperKine™ 超敏型ECL发光液（飞克级）	The IL-33/ST2 Axis protects retinal ganglion cells by modulating the astrocyte response after optic nerve injury.	5.800	Neuroscience Bulletin
BMU102	SuperKine™ 超敏型ECL发光液（飞克级）	Gastrodin enhances stress resilience through promoting Wnt/β-Catenin-dependent neurogenesis.	13.000	Journal of Advanced Research
BMU102	SuperKine™ 超敏型ECL发光液（飞克级）	Bromodomain-containing proteins interact with a non-canonical RNA polymerase II kinase to maintain gene expression upon heat stress.	13.600	Nature Plants
BMU102	SuperKine™ 超敏型ECL发光液（飞克级）	Using computational pharmacology and experimental verification to decode mechanism of Qing-Wei-San in treating periodontitis.	3.400	BMC Complementary Medicine and Therapies
BMU102	SuperKine™ 超敏型ECL发光液（飞克级）	Lactiplantibacillus plantarum ZJ316 alleviates Helicobacter pylori-induced intestinal inflammation by sustaining intestinal homeostasis.	4.400	Probiotics and Antimicrobial Proteins
BMU102	SuperKine™ 超敏型ECL发光液（飞克级）	Nobiletin: a potential erythropoietin receptor activator protects renal cells against hypoxia.	8.100	Apoptosis
BMU102	SuperKine™ 超敏型ECL发光液（飞克级）	Identifying the target, mechanism, and agonist of α-ketoglutaric acid in delaying mesenchymal stem cell senescence.	6.900	Cell Reports
BMU102	SuperKine™ 超敏型ECL发光液（飞克级）	Human umbilical cord mesenchymal stem cell-derived exosome ameliorate doxorubicin-induced senescence.	3.500	Experimental Cell Research
BMU102	SuperKine™ 超敏型ECL发光液（飞克级）	Network pharmacology and in vitro experiments reveal the potencial mechanism of Qizhiyishen Decoction against AKI.		Available at SSRN
BMU102	SuperKine™ 超敏型ECL发光液（飞克级）	LACTB-Induced ERBB3 Degradation Inhibits Lipid Synthesis and Suppresses Glioma Growth.

首页上一页 134 135 136 137 138 139 下一页尾页

赋能细胞研究与治疗 Enabling cell research and therapy

联系我们

全国服务热线： 400-6800-830

订购邮箱： service@abbkine.com

联系地址：武汉光谷生物医药加速器17号楼1号房2-3层

友情链接：

Copyright ©Abbkine Scientific Co., Ltd- 鄂ICP备10204150号-5

意见反馈

 在线咨询

扫码关注

微信公众号

返回顶部